Products

AmnioAMP-MP™ is a membrane allograft that may be used as a therapeutic active barrier agent in numerous clinical applications. The membrane forms a protective covering over the wound to preserve tissue structure and biologic integrity.  AmnioAMP-MP™ created with our proprietary PūrAMP Process™, offers mechanical protection and retains nutrient growth factors that are essential for signaling¹².  The product undergoes active preservation of the extracellular matrix (ECM), regulatory proteins, and removal of blood contaminants via a proprietary PūrAMP Process™.  AmnioAMP-MP™ is HCT/P compliant under section 361 of the Public Health Service Act according to 21 CFR Part 1271.10.  They are regulated as human cell product-for homologous use only.

AmnioAllograft™ is a non structural minimally manipulated liquid allograft derived from amniotic fluid that functions to cushion and protect the fetus in utero.  Amniotic fluid contains vital components, such as nutrients and infection fighting antibodies.  AmnioAllograft™ functions in the same homologous way of providing protection by acting as a shock absorber and temperature control through insulation.  Our PūrAMP Process™ never alters the native, regenerative properties of the allograft tissue; the integrity and characteristics are always maintained. AmnioAllograft™ is HCT/P compliant under section 361 of the Public Health Service Act according to 21 CFR Part 1271.10. They are regulated as human cell product-for homologous use only.

AmnioAMP-WJ™ contains isolated Wharton’s Jelly derived from the umbilical cord that provides cushioning and support to the umbilical vein and arteries.  Wharton’s Jelly does not exhibit an immune reaction or rejection, considered “immune privileged”.  Our proprietary PūrAMP Process™ does not alter the original tissue’s function as a Wharton’s Jelly connective tissue, providing physical support and cushioning.  AmnioAMP-WJ™ is regulated as human cell, tissue or cellular-tissue based product (HCT/P) 21 CFR Part 1271.10 and 361 of the Public Health Service Act.  They are regulated as human cell product-for homologous use only.